EPR19-066: Trends in Primary Squamous Cell Penile Cancer: A SEER Study

2019 ◽  
Vol 17 (3.5) ◽  
pp. EPR19-066
Author(s):  
Scott Cooper ◽  
Mohammed Zaher ◽  
Gregory Diorio
Keyword(s):  
Surgical Treatment ◽  
Squamous Cell ◽  
Penile Cancer ◽  
The United States ◽  
Advanced Age ◽  
Patient Specific ◽  
Cancer Specific Survival ◽  
Entire Study ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Objective: Although rare worldwide, primary squamous cell penile cancer (PSPC) is associated with significant psychological stress and cancer-specific mortality. We aim to analyze trends in PSPC in the United States from 2000–2015 using U.S. Surveillance, Epidemiology, and End Results registry (SEER). Clinical identification of risk factors for adverse outcomes will allow for patient-specific counseling on prognosis and intervention. Methods: Population-based data from SEER 18 was used to assess PSPC. SEER Stat was used to calculate incidence, mortality, and survival statistics of PSPC, as well as demographic, geographic, socioeconomic, and clinical variables from 2000 to 2015. Trends were assessed over 5-year spans (2000–2005, 2006–2010, and 2011–2015) using annual percent change. Kaplan-Meier logistic regression analysis was used to calculate 5-year, cancer-specific survival. Results: From 2000–2015, 5,144 men in the U.S. were diagnosed with PSPC at a rate of 0.38 per 100,000, which remained unchanged throughout the entire study period. Asians and Pacific Islanders had the lowest incidence (0.02, 95% CI=0.2, 0.2; P<.05) of all racial groups. Hispanics had a higher incidence (0.58, 95% CI=0.54, 0.62; P<.05) than non-Hispanics. Incidence was highest in the South (0.46, 95% CI=0.43, 0.48; P<.05); however, cancer-specific mortality was similar across regions. No difference in mortality was observed between urban and rural dwelling. Those lacking a high school education and living in areas with more than 10% poverty had a greater incidence of PSPC than others (P<.05). Overall, 5-year cancer-specific survival was 57%, which remained consistent across each studied time interval (P<.05). Compared to previous years, those diagnosed between 2011 and 2015 lacked surgical intervention, were of advanced age (>74–85 years), stage (T1, T2, T3), and with greater lymph node burden (>4) (P<.05). Increased mortality was associated with unmarried men, >20% poverty rate, advanced age, advanced T stage, and lack of surgical treatment (P<.05). Conclusion: Disparity in PSPC continues to exist. Incidence of penile cancer has increased with advanced age and stage. Unmarried, impoverished men with advanced stage and lack of surgical treatment have increased cancer-specific mortality. Efforts should be directed to those most at risk with hopes to identify disease at an earlier stage to provide surgical treatment with curative intent.

scholarly journals Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States

2015 ◽  
Vol 33 (21) ◽  
pp. 2376-2383 ◽  
Author(s):  
Anna E. Coghill ◽  
Meredith S. Shiels ◽  
Gita Suneja ◽  
Eric A. Engels
Keyword(s):  
Cancer Treatment ◽  
Cox Regression ◽  
B Cell Lymphoma ◽  
The United States ◽  
Cancer Stage ◽  
Infected People ◽  
Patients With Cancer ◽  
Increased Risk ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Purpose Despite advances in the treatment of HIV, HIV-infected people remain at increased risk for many cancers, and the number of non–AIDS-defining cancers is increasing with the aging of the HIV-infected population. No prior study has comprehensively evaluated the effect of HIV on cancer-specific mortality. Patients and Methods We identified cases of 14 common cancers occurring from 1996 to 2010 in six US states participating in a linkage of cancer and HIV/AIDS registries. We used Cox regression to examine the association between patient HIV status and death resulting from the presenting cancer (ascertained from death certificates), adjusting for age, sex, race/ethnicity, year of cancer diagnosis, and cancer stage. We included 1,816,461 patients with cancer, 6,459 (0.36%) of whom were HIV infected. Results Cancer-specific mortality was significantly elevated in HIV-infected compared with HIV-uninfected patients for many cancers: colorectum (adjusted hazard ratio [HR], 1.49; 95% CI, 1.21 to 1.84), pancreas (HR, 1.71; 95% CI, 1.35 to 2.18), larynx (HR, 1.62; 95% CI, 1.06 to 2.47), lung (HR, 1.28; 95% CI, 1.17 to 1.39), melanoma (HR, 1.72; 95% CI, 1.09 to 2.70), breast (HR, 2.61; 95% CI, 2.06 to 3.31), and prostate (HR, 1.57; 95% CI, 1.02 to 2.41). HIV was not associated with increased cancer-specific mortality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell lymphoma. After further adjustment for cancer treatment, HIV remained associated with elevated cancer-specific mortality for common non–AIDS-defining cancers: colorectum (HR, 1.40; 95% CI, 1.09 to 1.80), lung (HR, 1.28; 95% CI, 1.14 to 1.44), melanoma (HR, 1.93; 95% CI, 1.14 to 3.27), and breast (HR, 2.64; 95% CI, 1.86 to 3.73). Conclusion HIV-infected patients with cancer experienced higher cancer-specific mortality than HIV-uninfected patients, independent of cancer stage or receipt of cancer treatment. The elevation in cancer-specific mortality among HIV-infected patients may be attributable to unmeasured stage or treatment differences as well as a direct relationship between immunosuppression and tumor progression.

All-Cause 30-Day Mortality After Surgical Treatment for Head and Neck Squamous Cell Carcinoma in the United States

2019 ◽  
Vol 42 (7) ◽  
pp. 596-601 ◽  
Author(s):  
Aleksandr R. Bukatko ◽  
Parth B. Patel ◽  
Vindhya Kakarla ◽  
Matthew C. Simpson ◽  
Eric Adjei Boakye ◽  
...  
Keyword(s):  
United States ◽  
Squamous Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
The United States ◽  
Neck Squamous Cell Carcinoma

scholarly journals Light Cigarette Smoking Increases Risk of All-Cause and Cause-Specific Mortality: Findings from the NHIS Cohort Study

2020 ◽  
Vol 17 (14) ◽  
pp. 5122 ◽  
Author(s):  
Wen Qin ◽  
Costan G. Magnussen ◽  
Shengxu Li ◽  
Lyn M Steffen ◽  
Bo Xi ◽  
...  
Keyword(s):  
United States ◽  
Cigarette Smoking ◽  
Respiratory Disease ◽  
The United States ◽  
Hazard Ratios ◽  
Specific Mortality ◽  
Interview Survey ◽  
Disease Specific Mortality ◽  
Cancer Specific Mortality ◽  
Never Smokers

Very few studies have examined the association between light cigarette smoking (i.e., ≤5 cigarettes per day) and mortality. The aim of this study was to examine the association of light cigarette smoking with all-cause and cause-specific mortality among adults in the United States. Data were from 13 waves of the National Health Interview Survey (1997 to 2009) that were linked to the National Death Index records through December 31, 2011. A total of 329,035 participants aged ≥18 years in the United States were included. Deaths were from all cause, cancer, cardiovascular disease (CVD) and respiratory disease and were confirmed by death certification. During a median follow-up of 8.2 years, 34,862 participants died, of which 8415 were from cancer, 9031 from CVD, and 2040 from respiratory disease. Compared with never-smokers, participants who smoked 1–2 (hazard ratios (HR) = 1.94, 95%CI = 1.73–2.16) and 3–5 cigarettes (HR = 1.99, 1.83–2.17) per day were at higher risk of all-cause mortality after adjustment for demographic variables, lifestyle factors and physician-diagnosis of chronic disease. The associations were stronger for respiratory disease-specific mortality, followed by cancer-specific mortality and CVD-specific mortality. For example, the HRs (95% CIs) of smoking 1–2 cigarettes per day were 9.75 (6.15–15.46), 2.28 (1.84–2.84) and 1.93 (1.58–2.36), respectively, for these three cause-specific mortalities. This study indicates that light cigarette smoking increases risk of all-cause and cause-specific mortality in US adults.

Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis

2014 ◽  
Vol 66 (5) ◽  
pp. 811-814 ◽  
Author(s):  
Malte Rieken ◽  
Rosa S. Djajadiningrat ◽  
Luis A. Kluth ◽  
Ricardo L. Favaretto ◽  
Evanguelos Xylinas ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Disease Recurrence ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII).

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 4-4 ◽  
Author(s):  
Sophie D. Fossa ◽  
Anders Widmark ◽  
Olbjorn Harald Klepp ◽  
Fredrik Wiklund ◽  
Anders Angelsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Locally Advanced ◽  
Hormonal Treatment ◽  
Observation Time ◽  
Cancer Specific Survival ◽  
High Risk Prostate Cancer ◽  
Specific Mortality ◽  
Risk Prostate Cancer ◽  
Cancer Specific Mortality ◽  
Overall Mortality

4 Background: After a median observation time of 7.6 years, Scandinavian Prostate Cancer Group VII randomized trial showed a significant 12% reduction of prostate cancer-specific mortality in patients with locally advanced or histologically aggressive prostate cancer who received three months of total androgen blockade followed by radiotherapy and continuous antiandrogen therapy compared to patients with hormonal treatment only (Widmark et al :Lancet [2009]; 373,1174). Here we provide the 10 (15)-year survival results after a median observation time of 10.7 years. Methods: Between February 1996 and December 2002, 875 patients with locally advanced prostate cancer were randomized (Randomization ratio 1:1). Primary endpoint was prostate cancer-specific survival analyzed by intention to treat. This updated analysis is based on death registry data of the Norwegian patients (2/3 of the population), and on data recorded in CRF database available for the Swedish patients. A Swedish death registry analysis is underway, and will be included in the final analysis at the meeting. Results: Prostate cancer death occurred in 118 out of 439 of the antiandrogen treatment group and in 45 out of 436 men in the combination treatment group (p< 0.0001), with death due to any cause in 210 out of 439 and 161 out of 436 men (p=0.0006), respectively. The 10 (15) year cumulative prostate cancer-specific mortality was more than halved after combined treatment: 18.9% (30.7%) and 8.3% (12.4%) (HR=0.35;[p<4.1E-10 for 15 year results]), and overall mortality was 35.3% (56.7%) and 26.4% (43.4%) (HR=0.70; P=0.0006 for 15 year results), respectively. Conclusions: Addition of local radiotherapy to hormonal treatment in patients with non-metastatic locally advanced or high-risk prostate cancer more than halved the 10 and 15 year prostate cancer-specific mortality and substantially decreased overall mortality.

Metastatic-free intervals and risk of breast cancer-specific mortality among patients with hormone receptor-positive breast cancer: A population-based analysis from the Surveillance, Epidemiology, and End Results registries.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13034-e13034
Author(s):  
Gregory Sampang Calip ◽  
Ernest H Law ◽  
Colin Hubbard ◽  
Nadia Azmi Nabulsi ◽  
Alemseged Ayele Asfaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Population Based ◽  
Breast Cancer Specific Survival ◽  
Cancer Specific Survival ◽  
Breast Cancer Specific Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Positive Breast Cancer

e13034 Background: Patients successfully treated for hormone receptor (HR)-positive early breast cancer remain at risk of recurrence and metastatic disease even after extended periods of disease-free years. Whether prolonged metastatic-free intervals ultimately confer a benefit to breast cancer-specific survival is not well understood. This study aimed to investigate metastatic-free intervals and risk of breast cancer-specific mortality among patients with HR-positive breast cancer after adjuvant therapy. Methods: We conducted a retrospective cohort study of women aged 18 years and older diagnosed with recurrent metastatic HR-positive breast cancer between 1990 and 2016 in the Surveillance, Epidemiology, and End Results registries. Patients with longitudinal information on primary stage I-III HR-positive breast cancer through the occurrence of metastatic disease and survival were included. Risks of breast cancer-specific mortality associated with metastatic-free intervals (defined as time from primary breast cancer diagnosis to metastasis) of ≥5 years compared to < 5 years were estimated. Fine and Gray competing risks regression models were used to calculate subdistribution hazard ratios (SHR) and 95% confidence intervals (CI). Results: Among 1,057 women with HR-positive breast cancer with a median age of 54 years at primary breast cancer diagnosis and 62 years at metastatic progression, 65% of women had a metastatic-free disease interval ≥5 years, whereas 35% had an interval of < 5 years. Overall, patients with metastatic-free intervals < 5 years had a five-year breast cancer-specific survival rate of 31% compared to 52% in women with intervals of ≥5 years. In multivariable analyses adjusted for age, race, diagnosis year, grade, treatment and sites of metastasis, patients with intervals of ≥5 years had decreased risk of breast cancer-specific mortality (SHR = 0.72, 95% CI 0.58-0.89, P = 0.002) compared to women with metastatic-free intervals of < 5 years. Conclusions: In this population-based study, rates of cancer-specific mortality among patients who experienced metastatic recurrence of HR-positive breast cancer were lower in women with metastatic-free intervals of 5 years or more. The results of this study may inform patient-clinician discussions surrounding prognosis and treatment selection among HR-positive patients.

Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era

2003 ◽  
Vol 21 (11) ◽  
pp. 2163-2172 ◽  
Author(s):  
Anthony V. D’Amico ◽  
Judd Moul ◽  
Peter R. Carroll ◽  
Leon Sun ◽  
Deborah Lubeck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Risk Groups ◽  
The United States ◽  
Localized Prostate Cancer ◽  
Institutional Setting ◽  
Psa Failure ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Purpose: To determine whether pretreatment risk groups shown to predict time to prostate cancer–specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting. Patients and Methods: From 1988 to 2002, 7,316 patients treated in the United States at 44 institutions with either surgery (n = 4,946) or radiation (n = 2,370) for clinical stage T1c-2, N0 or NX, M0 prostate cancer made up the study cohort. A Cox regression analysis was performed to determine the ability of pretreatment risk groups to predict time to PCSM after treatment. The relative risk (RR) of PCSM and 95% confidence intervals (CIs) were calculated for the intermediate- and high-risk groups relative to the low-risk group. Results: Estimates of non-PCSM 8 years after prostate-specific antigen (PSA) failure were 4% v 15% (surgery versus radiation; Plog rank = .002) compared with 13% v 18% (surgery versus radiation; Plog rank = .35) for patients whose age at the time of PSA failure was less than 70 as compared with ≥ 70 years, respectively. The RR of PCSM after treatment for surgery-managed patients with high- or intermediate-risk disease was 14.2 (95% CI, 5.0 to 23.4; PCox < .0001) and 4.9 (95% CI, 1.7 to 8.1; PCox = .0037), respectively. These values were 14.3 (95% CI, 5.2 to 24.0; PCox < .0001) and 5.6 (95% CI, 2.0 to 9.3; PCox = .0012) for radiation-managed patients. Conclusion: This study provided evidence to support the prediction of time to PCSM after surgery or radiation on the basis of pretreatment risk groups for patients with clinically localized prostate cancer managed during the PSA era.

976 LOCATION OF PRIMARY TUMOR PREDICTS CANCER-SPECIFIC MORTALITY IN SQUAMOUS CELL CARCINOMA OF THE PENIS

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Mark Tyson ◽  
Eric Wisenbaugh ◽  
Paul Andrews ◽  
Mitchell Humphreys ◽  
Robert Ferrigni ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Specific Mortality ◽  
Cancer Specific Mortality

scholarly journals Imaging for the Initial Staging and Post-Treatment Surveillance of Penile Squamous Cell Carcinoma

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 170
Author(s):  
Samuel J. Galgano ◽  
John C. Norton ◽  
Kristin K. Porter ◽  
Janelle T. West ◽  
Soroush Rais-Bahrami
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Penile Cancer ◽  
The United States ◽  
Positron Emission ◽  
Ultrasound Computed Tomography ◽  
Penile Squamous Cell Carcinoma ◽  
Almost All ◽  
Initial Staging

Although relatively rare in the United States, penile squamous cell carcinoma is encountered worldwide at a higher rate. Initial diagnosis is often made on clinical exam, as almost all of these lesions are externally visible and amenable to biopsy. In distinction to other types of malignancies, penile cancer relies heavily on clinical nodal staging of the inguinal lymph node chains. As with all cancers, imaging plays a role in the initial staging, restaging, and surveillance of these patients. The aim of this manuscript is to highlight the applications, advantages, and limitations of different imaging modalities in the evaluation of penile cancer, including ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography.

Sign in / Sign up

Export Citation Format

Share Document